ABO-102 Gene Therapy for Type A Patients Continues to Show Key and Durable Benefits in Trial, Abeona Reports
Sanfilippo syndrome type A patients treated with the gene therapy candidate ABO-102 continue to show robust and sustained clinical improvements in a Phase 1/2 trial, its developer, Abeona Therapeutics, reports. The company presented updated results of its open-label study (NCT02716246) at the recent American Society for…